MedTrace Logo

A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria

NCT06295302 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-03-07

No results posted yet for this study

Summary

This is a multicenter, randomized, double-bind and placebo-controlled phase IIa dose-finding study to assess the safety and efficacy of HWH486 in adults with chronic spontaneous urticaria (CSU). In addition, the pharmacokinetic characteristics will also be investigated.

Conditions

Interventions

DRUG

HWH486

HWH486 capsule was administrated orally

DRUG

Placebo

Matching placebo was administrated orally

Sponsors & Collaborators

  • Hubei Biological Medicine Industrial Technology Institute Co., Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-13
Primary Completion
2025-12-31
Completion
2026-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06295302 on ClinicalTrials.gov